ACKNOWLEDGEMENTS

ABOUT THE AMERICAN BRAIN TUMOR ASSOCIATION

Founded in 1973, the American Brain Tumor Association (ABTA) was the first national nonprofit organization dedicated solely to brain tumor research. For over 40 years, the Chicago-based ABTA has been providing comprehensive resources that support the complex needs of brain tumor patients and caregivers, as well as the critical funding of research in the pursuit of breakthroughs in brain tumor diagnosis, treatment and care.

To learn more about the ABTA, visit www.abta.org.

We gratefully acknowledge Regina Jakacki, MD, director, Pediatric Neuro-Oncology Program, Children’s Hospital of Pittsburgh, Pittsburgh, Pennsylvania and Beverly LaVally, RN, of the Dana-Farber Cancer Institute, Boston, for their review of this edition of this publication.

This publication is not intended as a substitute for professional medical advice and does not provide advice on treatments or conditions for individual patients. All health and treatment decisions must be made in consultation with your physician(s), utilizing your specific medical information. Inclusion in this publication is not a recommendation of any product, treatment, physician or hospital.

COPYRIGHT © 2015 ABTA
REPRODUCTION WITHOUT PRIOR WRITTEN PERMISSION IS PROHIBITED
Ependymoma

INTRODUCTION

Any tumor that arises from the glial cells in the brain is called a “glioma.” Glial cells provide support and protection for the nerve cells, or neurons, in the brain. One type of glioma is the ependymoma. Ependymomas arise from ependymal cells that line the ventricles of the brain and the center of the spinal cord. Occasionally, ependymal cells are found within the brain itself. Ependymomas are soft, grayish or red tumors which may contain cysts or mineral calcifications.

The words “supratentorial” and “infratentorial” describe the location of the ependymoma within the brain. The tentorium is a thick membrane that separates

![Diagram of brain with labeled parts](Image)
the top two-thirds of the brain from the bottom third. Supratentorial ependymomas occur above the tentorium. This area includes the cerebral hemispheres, as well as the lateral and the third ventricles. Infratentorial ependymomas occur below the tentorium. This area, also called the posterior fossa, includes the fourth ventricle, the brainstem and the cerebellum.

There are four major types of ependymomas: myxopapillary ependymomas, subependymomas, ependymomas and anaplastic ependymomas.

Many pathologists also assign a number “grade” to ependymomas. The grade is based on how much the cells look like normal ependymal cells, although various grading systems exist. While the cells of a grade I tumor look somewhat unusual compared to normal ependymal cells, grade III tumor cells look definitely abnormal.

Most grade I tumors do not recur after complete surgical removal. Grades II and III tumors need additional treatment and have a higher likelihood of recurring.

Myxopapillary ependymomas tend to occur in the lower part of the spinal column. Subependymomas usually occur near a ventricle. Both are slow growing, and are considered to be low-grade or grade I tumors.

Ependymomas are the most common of the ependymal tumors, and are considered grade II tumors. These tumors are usually located along, within or adjacent to the ventricular system, often in the posterior fossa or in the spinal cord.

Anaplastic ependymomas are high-grade tumors (grade III) and tend to be faster growing than low-grade tumors. They most commonly occur in the posterior fossa.
INCIDENCE
Ependymomas are relatively rare tumors, accounting for 2–3% of all primary brain tumors. However, they are the third most common brain tumor and spinal cord tumor in children. About 30% of pediatric ependymomas are diagnosed in children younger than three years of age.

The location of ependymomas in adults tends to be different than the location of ependymomas in children. In adults, 60% of these tumors are found in the spinal cord. In children, 90% of ependymomas are found in the brain, with the majority located in the posterior fossa.

CAUSE
The cause of ependymomas, like that of other brain tumors, is unknown. Much more research is necessary to determine whether this is indeed a factor in humans, since these particular viruses do not normally affect humans.

SYMPTOMS
Symptoms of an ependymoma are related to the location and size of the tumor. In neonates and infants, enlargement of the head may be one of the first symptoms. Irritability, sleepiness and vomiting may develop as the tumor grows. In older children and adults, nausea, vomiting and headache are the most common symptoms. These are usually signs of increased pressure or hydrocephalus, which develops if the tumor blocks the drainage of cerebrospinal fluid (the liquid that bathes the brain).

Fatigue is a common symptom people experience during the course of the illness.

Headaches are a common symptom, and are generally worse in the morning. A tumor near the brainstem may cause one or both eyes to cross, balance problems or trouble walking.
Neck pain may result from a tumor growing near the brainstem or the upper part of the spinal cord. Seizures, headaches and weakness of one side or one part of the body may occur with a tumor in the cerebral hemispheres. Spinal cord tumors often cause leg or back pain which can be severe enough to awaken the person from sleep. Tingling sensations, numbness, or weakness in the arms or legs may also occur. Difficulty with bladder or bowel control may be caused by an ependymoma in the lower part of the spine.

**DIAGNOSIS**

Magnetic Resonance Imaging (MRI) scans and/or Computerized Axial Tomography (CT) scans are required for patients suspected of having a brain tumor. The MRI, which uses radio waves and a magnetic field, provides details about the location of the tumor and which parts of the brain or spinal cord are involved prior to surgery. CT scanners are sophisticated x-ray devices connected to computers. CT scans are useful
for getting a quick view of the brain to see if there is a tumor and whether it has caused hydrocephalus (the buildup of cerebrospinal fluid in the brain). However, only microscopic examination of a sample of tissue obtained during surgery or biopsy confirms the exact diagnosis.

About 10–15% of ependymomas spread, or metastasize, through the cerebrospinal fluid. The tumor cells then may grow independently, in or along the spinal cord, or rarely, in other places in the brain. Infratentorial tumors are more likely to spread to the spine than supratentorial tumors. Ependymomas almost never spread outside of the central nervous system (brain and spinal cord). A spinal MRI scan and lumbar puncture (spinal tap) will be performed to determine whether the tumor has spread to the spine and/or spinal fluid. The fluid obtained during the spinal tap will be tested for the presence of tumor cells. Your doctor will decide the appropriate time to perform these tests. The results are used to guide treatment.

**TREATMENT**

With improved neurosurgical and radiation therapy techniques, patients with ependymomas have a significantly increased chance of survival, particularly if they are cared for by an experienced multidisciplinary team of medical professionals at an established pediatric or adult cancer center with a brain tumor specialty.
The treatment of an ependymoma varies depending on its location, grade, and whether the tumor has spread to the spine.

**SURGERY**

The most important first step in the treatment of an ependymoma is surgery to remove as much tumor as possible. Studies clearly show that patients whose tumor can be “grossly” removed (removing all tumor that can be seen) have the best chance of long-term survival. The amount of tumor that can be removed, however, depends on the location of the tumor. High-powered microscopes in the operating room help the surgeon see tumor located in and around the ventricles or the brainstem. Removal of all visible tumor is not always possible, especially if the tumor is attached to the brainstem or involves other important areas of the brain. In children, ependymomas often fill the fourth ventricle and extend through its floor into the brainstem, or out to the side of the lower brainstem where the nerves that affect swallowing are located, making safe removal of those portions of tumor difficult.
Hydrocephalus is often present at the time of diagnosis when the tumor has blocked the outflow of cerebrospinal fluid. Tumor removal may open up these fluid pathways, although some patients will still require the placement of a ventriculoperitoneal (VP) shunt to bypass the blockage. Many surgeons will place a temporary external ventricular drain during surgery. This is used to drain off excess fluid for a few days after the surgery. If it cannot be removed after a few days, a permanent shunt may be required.

An MRI of the brain should be done within a day or two of surgery to determine how much visible tumor remains, if any.

**RADIATION**

Radiation therapy is usually recommended for older children (age dependent on the location of the tumor) and adults following surgery, even if all visible tumor was removed.

The age of the patient, the location of the tumor and whether it has spread are considered in treatment planning. If the tumor is localized, radiation therapy is usually given just to that area of the brain. If the tumor has spread, radiation is usually given to the entire brain and spine, with an extra amount of radiation (called a boost) given to the area of the brain where the tumor started.

There are different methods of administering radiation. External beam radiation is given five days a week for six weeks. Conformal beam radiation therapy is a type of external beam radiation that contours the radiation beams to the shape of the tumor. Proton radiation therapy uses beams of fast-moving protons to destroy tumors. Stereotactic radiosurgery is a way of giving a single or a few high doses of precisely focused radiation
to the tumor. This is often used for ependymomas that grow back after conventional radiation. Your doctor will decide which form of radiation is best for you.

Because of the long-term side effects of radiating young children, chemotherapy may be used to delay radiation therapy in the very young child. If the tumor grows despite the chemotherapy, radiation therapy may be considered.

**CHEMOTHERAPY**

Chemotherapy uses special drugs to kill tumor cells. Scientists continue to study the role of chemotherapy and when it is best used. It is not clear whether using chemotherapy in the treatment of patients with newly diagnosed ependymomas makes a difference. Some tumors respond to treatment for awhile, while others continue to grow. Chemotherapy may also be used to delay radiation for infants and young children, or to treat tumors that have grown back after radiation therapy. It is not clear which chemotherapy drugs are the most effective against ependymomas. Drugs such as cisplatin and carboplatin may cause shrinkage in about half of ependymomas, although not usually for a long time. Either standard chemotherapy, or experimental chemotherapy as part of a clinical trial, are often used for patients whose tumors regrow after radiation.

**TREATMENT SIDE EFFECTS**

Some treatment, while increasing survival, may have significant side effects on children. Prior to treatment your child may undergo neuropsychological testing. Those results can be used as a baseline for future evaluations.

Surgery, particularly for infratentorial ependymomas, may result in the development or temporary worsening of balance, speech or swallowing. Most of these changes will improve over several weeks
or months. The negative effects of radiation therapy on the brain are of great concern to those who treat children with brain tumors. A significant number of children, particularly those who are very young at the time of treatment, experience some degree of decreased intellect and learning problems following radiation to large areas of the brain. The severity of the learning problems is correlated with the location and amount of brain radiated and inversely related to the age of the child. Radiation to just the back part of the brain does not cause as many problems as does radiation to the upper part of the brain. When the upper part of the brain is radiated, teachers and parents often report significant problems with reading, math and short-term memory. The role of special education programs to help these children develop their strengths and identify their weaknesses is of prime importance.

Older children and adults tend to have fewer problems. Poor growth may be a consequence of radiation therapy damage to the hypothalamus or pituitary gland which produce several important hormones. Replacement of these hormones is often necessary, under the supervision of a pediatric endocrinologist. Radiation to the spine at a young age may also cause short stature. Weakening of the muscles next to the spine is also possible.

The long-term effects of chemotherapy in children are still being studied. Platinum-based drugs often cause
hearing loss, as can radiation therapy when delivered near the ears. Both radiation and chemotherapy can increase the chance of developing a second cancer or brain tumor. Some chemotherapy can cause infertility.

The risk of incurring long term side effects due to treatment must be weighed against the outcome if these therapies are not administered. Your doctor can help you look at these concerns and understand the risks based on your child's particular treatment plan, as well as help you balance the benefits of therapy against the potential risks.

**FOLLOW-UP**

MRI scans of the brain and/or spinal cord are usually done every three to four months for the first two years following diagnosis. These scans are used to determine the effectiveness of treatment and to watch for possible recurrence. Scans are done less frequently thereafter, unless symptoms develop which might indicate tumor growth. Your doctor will determine the appropriate schedule.

**RECURRENTCE**

The extent of tumor removal continues to be the strongest factor influencing recurrence and survival. Age at diagnosis, amount of tumor remaining after surgery, whether the tumor has spread, and the therapy given can all influence outcome. Researchers are also studying the biologic features of these tumors to determine which may be useful in predicting prognosis.

For patients whose tumors recur after initial treatment, re-operation when possible, followed by additional therapy, can be helpful. Newer investigational treatments include various forms of chemotherapy, and re-irradiation (possibly with radiosurgery) to the areas of tumor recurrence.
THE ABTA IS HERE FOR YOU
You don’t have to go through this journey alone. The American Brain Tumor Association is here to help.

Visit us at www.abta.org to find additional brochures, read about research and treatment updates, connect with a support community, join a local event and more.

We can help you better understand brain tumors, treatment options, and support resources. Our team of health care professionals are available via email at abtacares@abta.org or via our toll-free CareLine at 800-886-ABTA (2282).
NOTES/QUESTIONS
AMERICAN BRAIN TUMOR ASSOCIATION
PUBLICATIONS AND SERVICES

CARE & SUPPORT
CareLine: 800-886-ABTA (2282)
Email: abtacares@abta.org

PUBLICATIONS

About Brain Tumors: A Primer for Patients and Caregivers

Tumor Types:
Ependymoma
Glioblastoma and Malignant Astrocytoma
Medulloblastoma
Meningioma
Metastatic Brain Tumors
Oligodendroglioma and Oligoastrocytoma
Pituitary Tumors

Treatments:
Chemotherapy
Clinical Trials
Conventional Radiation Therapy
Proton Therapy
Stereotactic Radiosurgery*
Steroids
Surgery

All publications are available for download in Spanish.
(exception is marked *)

CLINICAL TRIALS

TrialConnect®: www.abtrialconnect.org or 877-769-4833

More brain tumor resources and information are available at www.abta.org.
For more information contact:

CareLine: 800-886-ABTA (2282)
Email: abtacares@abta.org
Website: www.abta.org

To find out how you can get more involved locally, contact volunteer@abta.org or call 800-886-1281